NCT01719640

MSC and MC in Type 2 Diabetes Mellitus

Autologous Bone Marrow Mesenchymal Stem Cell and Bone Marrow Mononuclear Cell Infusion in Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Fuzhou General Hospital · Academic / Other
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Cell injury in human islets induced by non-immune mediated inflammation occur in vitro upon hyperglycemia in type 2 diabetes mellitus. Infusion of autologous bone marrow mononuclear cells (MCs) is an emerging therapeutic approach for DM, which showed promising outcomes with mild side effects. Infusion of MCs and autologous bone marrow mesenchymal stem cells in combination might exert enhanced repairing effects. We hypothesized that infusion of these two classes of cells might provide multiple signals for regeneration and improve recovery from inflammation-induced lesion. The effects might be maximized by intra-arterial pancreatic infusion.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	infusion of MSCs	infusion of MSCs
DRUG	infusion MCs	infusion of MCs
DRUG	insulin	intensive insulin care

Timeline

• Start date: 2011-01-01
• Primary completion: 2013-01-01
• Completion: 2020-01-01
• First posted: 2012-11-01
• Last updated: 2023-01-12

Locations

1 site across 1 country: China